Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.

Slides:



Advertisements
Similar presentations
June 20, 2005 Pharmaceutical Misuse & Abuse: from National to Local What the Data Say and Mean for Montgomery County Public Schools Presenter: Kenneth.
Advertisements

National Prescription Drug Threat Assessment 2009 National Drug Intelligence Center Drug Enforcement Administration.
Diversion Alert. Prescription Monitoring Program Trends among Individuals Arrested in Maine for Trafficking Prescription Drugs, 2014 Christina Holt, MD,
Preventing Prescription Drug Abuse: Laws and Legislation Hollie Hendrikson, MSc Policy Specialist, Health Program.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.
National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.
OVERDOSE SOLUTIONS 2013 OVERDOSE DATA FOR ALLEGHENY COUNTY Jennifer Janssen Manager Toxicology Laboratory Allegheny County Office of the Medical Examiner.
Rx for Drug-Seeking Patients in the ED The Monterey County Prescribe Safe Initiative 1.
TM Centers for Disease Control and Prevention National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
2008 International Symposium on Pharmaceuticals in the Home PMP/TDS Update Debra Brucker, M.P.A., Ph.D. Daniel Eccher, M.P.H. Maine Office of Substance.
VIRGINIA PRESCRIPTION MONITORING PROGRAM C.A.R.E Presentation February 27, 2015 Ralph Orr Director, Virginia Prescription Monitoring Program.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Maine’s Prescription Monitoring Program Maine Benzodiazepine Study Group Conference 2007 UPDATE Daniel J. Eccher, MPH Project Coordinator.
Richland County Safety Council BWC Pharmacy Program Drug Utilization Management Outcomes John Hanna, R.Ph. BWC, Pharmacy Director 7/13/2015BWC Pharmacy.
Using the Maine PMP to Improve Prescribing Practices for Potentially Addictive Prescription Medications Susan Payne, MPH, PhD Research Professor Institute.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
The South Florida Report January 2013 National Institute on Drug Abuse Community Epidemiology Work Group James N. Hall Report # 56 Center for Applied Research.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
Prescription Drug Abuse/Misuse in Florida 2010 Florida Prevention Conference Orlando, Florida September 30, 2010 Hal Johnson, MPH Substance Abuse Program.
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
Richard Z Aramini, PharmD PGY-1 Pharmacy Practice Resident Bay Pines VA Healthcare Center.
The Prescription Behavior Surveillance System: Applications of De-identified PDMP Data in Public Health Surveillance Rx Abuse Summit April 23, 2014 Peter.
1. 2 National Institute on Drug Abuse Community Epidemiology Work Group (CEWG) Established 1976.
For Pain or Not for Pain: Methadone Madness
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
Adolescent Outlook and Outcomes FY 2010 Maryland Alcohol and Drug Abuse Administration (ADAA) Thomas P. Cargiulo, Pharm. D., Director.
Broward County Report Substance Abuse Issues and Trends – Winter 2013 James N. Hall.
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Broward Quick Check September 2012 Drug Abuse Patterns and Trends Update James N. Hall, Epidemiologist Center for Applied Research on Substance Use and.
The Impact of Integrated HIV Care on Patient Health Outcomes Tuyen Hoang, PhD Matthew B. Goetz, MD, Elizabeth Yano, PhD, Barbara Rossman, PhD, Henry D.
SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid.
Maine’s Prescription Monitoring Program Daniel J. Eccher, MPH Project Coordinator Prescription Drug Misuse: A Community Challenge.
LECTURE FOR ASSIGNMENT 1 AND 2
Introduction Results and Conclusions On counselor background variables, no differences were found between the MH and SA COSPD specialists on race/ethnicity,
Substance Use among Older Adults (Age 50+): Current Prevalence and Future Expectations Presented by Joe Gfroerer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.
State-level Influences on Buprenorphine Utilization: Variations in Opioid Addiction Treatment Lisa M. Lines, MPH and Robin E. Clark, PhD University of.
Finding a Predictive Model for Post-Hospitalization Adverse Events Henry Carretta 1, PhD, MPH; Katrina McAfee 1,2, MS; Dennis Tsilimingras 1,3, MD, MPH.
Health care trajectories and medication consumption of substance users in treatment : linking TDI and IMA databases (Belgium) De Ridder Karin, Antoine.
John Lipovsky, MPPM, AREM, PMM
Prescription Drug Abuse in Indiana
The Latest Prescription Trends for Controlled Prescription Drugs
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Inside Maine’s Medicine Cabinet. Inside Maine’s Medicine Cabinet: Analysis of the Maine Prescription Monitoring Program, Christina Holt, MD,
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Medstat MercuryMD Micromedex PDR Solucient Substance abuse medications: Trends and prescribing patterns by physician specialty November 5, 2007 American.
Drug Enforcement Administration Greater Kansas City Chapter American Society for Pain Management Nursing October 24, 2015 Judy R. Williams Group Supervisor.
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
The Prescription Opioid & Heroin Crisis: Addiction & Medication Assisted Treatment Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Pennsylvania's Prescription Drug Monitoring Program (PDMP) May 17, 2016.
Initiatives Toward A Public Health Approach
Jessica E. Bates, Pharm.D. PGY-1 Pharmacy Resident
THE OPIOID CRISIS Mississippi Board of Nursing
American Public Health Association Annual Meeting November 5, 2007
An Overview of the ePDMP
Prescription Drug Monitoring Program Facts, Figures, and Trends 3rd Quarter 2017 North Dakota Board of Pharmacy Kathy Zahn, CPhT, PDMP Program Administrator.
Drug-Related Deaths in Suffolk Alison Amstutz Senior Health Improvement Commissioner (Sexual Health and Drugs and Alcohol) Public Health, Suffolk County.
ROOM project Addressing the Opioid Epidemic in the U.P.
Prepared for the 2018 Maryland Highway Safety Summit
Pharmaceutical Abuse Trends in Maine
Opioid Use in Delaware: 2018 State Epidemiological Profile
2018 Delaware State Epidemiological Profile
Illinois Prescription Monitoring Program
PMP Advisory Committee
Recidivism Among DWI Offenders in New Mexico (Preliminary Results)
Center for Behavioral Health Statistics and Quality
Presentation transcript:

Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring Program, Kenneth McCall, PharmD Chunhao Tu, PhD Matthew Lacroix, PharmD Kevin Wallace, MD Christina Holt, MD Jonathan Balk, PharmD Candidate

Outline Background Pharmacoepidemiological PMP Analysis – Methods – Prescription trends from – Physician and pharmacy utilization patterns Future Directions

BACKGROUND

4 Maine PMP Overview Established in 2004 Data from over 300 retail and mail-order pharmacies licensed to dispense in Maine Data submitted at least twice per month. Data available to health care professionals (e.g., pharmacists and prescribers) online (after registration – only 40% of prescribers and 15% of pharmacists) Quarterly threshold reports sent to prescribers

Non-heroin opiate admissions by state per 100,000 population aged 12 and older:

MAINE LEADS THE NATION IN ADMISSIONS FOR PRESCRIPTION OPIOID ABUSE

Non-heroin opiate admissions by state per 100,000 population aged 12 and older: Source: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS), Data received through

Non-heroin opiate admissions by state per 100,000 population aged 12 and older: Source: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS), Data received through

Non-heroin opiate admissions by state per 100,000 population aged 12 and older: Source: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS), Data received through

MAINE LEADS THE NATION IN ADMISSIONS FOR PRESCRIPTION OPIOID ABUSE

IN MAINE, THERE WERE MORE ADMISSIONS FOR PRESCRIPTION OPIOID ABUSE IN 2010 THAN FOR ALCOHOL

Poisoning deaths involving opioid analgesics, cocaine, and heroin: US,

Death rates for poisonings involving opioid analgesics: Comparison of state and US rates: 2006

IN MAINE, THERE ARE MORE DEATHS EACH YEAR FROM OPIOID POSIONING THAN FROM AUTOMODILE ACCIDENTS

Pharmacoepidemiological PMP Analysis

Methods Design – Retrospective dataset analysis. – The Maine PMP began in 2004 and collects Schedule II, III, and IV new and refill prescription information from licensed pharmacies. – Individuals who received one or more controlled substance prescriptions from a licensed pharmacy during state fiscal years 2006 to 2010 (July 1, 2005 to June 30, 2010; herein referred to by year only) are included in the study population. – Data was cleaned and coded prior to analysis.

Methods Analysis – The two-sided Welch’s two-sample t test was used to compare the difference between two groups for continuous variables. – The Chi-square test was applied to examine the statistical association between two categorical variables and equal proportions, and the Cochran-Mantel-Haenszel (CMH) test was used to examine the associations between classes for multiple categorical data groups. – The association between ordinal variables 13 was measured using gamma statistics (  ) with corresponding 95% confidence interval (CI) and significance testing for temporal trends was performed with the Cochran- Armitage test.

PRESCRIPTION TRENDS FROM

Unique Patients Per Year Maine PMP Number of Unique Patients Patients / YearTrend Line

Number of unique patients per year increased by 31,653 from , while the US census bureau estimates the Maine population only grew by around 5,000

Number of Prescriptions by Drug Enforcement Agency (DEA) Class, Maine PMP Data, % Increase, P < % Increase, P < 0.001

Prescriptions for controlled drugs increased by 22.4% in 5 years, whereas the estimated Maine population only increased by 0.4%.

Class II drugs, which have the highest potential for abuse, had the greatest rate of increase in prescriptions among DEA classes from 2006 to 2010.

Frequency of Prescriptions by Drug Category, Maine PMP Data, 2006 & 2010

Narcotics are the most frequently prescribed drug category and stimulants are the fastest growing drug category.

Narcotic Prescriptions, Maine PMP, Fiscal Year# of RxsDays-Supply / Rx mean (SD) 20061,125, % Increase P < (12.50) 16.7% Increase P < ,177, (12.66) 20081,250, (12.82) 20091,271, (13.48) 20101,268, (13.45)

Hypnotic Prescriptions, Maine PMP, Fiscal Year# of RxsDays-Supply / Rx mean (SD) , % Increase P < (17.03) 9.8% Increase P < , (17.37) , (17.99) , (19.32) , (19.60)

Stimulant Prescriptions, Maine PMP, Fiscal Year# of RxsDays-Supply / Rx mean (SD) , % Increase P < (11.02) 2.8% Increase P < , (11.05) , (11.59) , (12.83) , (13.18)

The mean days-supply per prescription has significantly increased for all controlled drug categories; narcotics, hypnotics, and stimulants.

Oxycodone Prescriptions, Maine PMP, Fiscal Year# of RxsMean Dose Strength (mg) , % Increase P < % Increase P < , , , ,

Alprazolam Prescriptions, Maine PMP, Fiscal Year# of RxsMean Dose Strength (mg) , % Increase P < % Increase P < , , , ,

Amphetamine/dextroamphetamine Prescriptions, Maine PMP, Fiscal Year# of RxsMean Dose Strength (mg) , % Increase P < % Increase P < , , , ,

The mean dose per tablet of oxycodone, alprazolam, and amphetamine/dextroamphetamine has significantly increased.

Percent increase in Controlled Substance Rxs, CII Rxs, Days- supply per Rx (narcotics), and Strength per dose (oxycodone): Indexed to 2006 Levels Maine PMP Data

GRAMS of amphetamine/dextroamphetamine and oxycodone dispensed each year: Maine PMP Data, % Increase, P < % Increase, P < 0.001

In 2010, more than 300,000 grams of oxycodone and nearly 100,00 grams of amphetamine were dispensed to patients in Maine. Compared to 2006, this represents a significant 58.5% and 53.1% increase, respectively.

PHYSICIAN AND PHARMACY UTILIZATION PATTERNS

Distribution of individuals (number/%) receiving controlled prescriptions by number of prescribers and number of pharmacies in 2010 Number of Prescribers Used Number of Pharmacies Used 1234>5>5Total 1 246, , , , , , , , , , , , , , , , , , , >5>5 5, , , , , , Total341, , , , , ,

Most individuals (82.7%) obtained their prescriptions for controlled drugs from one or two prescribers in 2010.

Distribution of individuals (number/%) receiving controlled prescriptions by number of prescribers and number of pharmacies in 2010 Number of Prescribers Used Number of Pharmacies Used 1234>5>5Total 1 246, , , , , , , , , , , , , , , , , , , >5>5 5, , , , , , Total341, , , , , ,

Most individuals (93.6%) received their prescribed controlled drugs from one or two pharmacies in 2010.

Distribution of individuals (number/%) receiving controlled prescriptions by number of prescribers and number of pharmacies in 2010 Number of Prescribers Used Number of Pharmacies Used 1234>5>5Total 1 246, , , , , , , , , , , , , , , , , , , >5>5 5, , , , , , Total341, , , , , ,

The vast majority of individuals who used only one prescriber also used a single pharmacy (92.5%).

Distribution of individuals (number/%) receiving controlled prescriptions by number of prescribers and number of pharmacies in 2010 Number of Prescribers Used Number of Pharmacies Used 1234>5>5Total 1 246, , , , , , , , , , , , , , , , , , , >5>5 5, , , , , , Total341, , , , , , ([  = 0.711; 95% CI = (0.709, 0.714)])

The greater the number of prescribers, the more likely the prescription recipient used a greater number of pharmacies ([  = 0.711; 95% CI = (0.709, 0.714)]).

Number and percent of Schedule II, III, or IV prescription recipients who used five or more physicians, five or more pharmacies, either or both in DEA Class>5 Prescribers >5 Pharmacies >5 Prescribers OR >5 Pharmacies >5 Prescribers AND >5 Pharmacies II 4, % 1, % 5, % % III 3, % % 3, % % IV2, % % 2, % % A significantly greater percentage of individuals taking Schedule II drugs used five or more prescribers and/or five or more pharmacies than those taking only Schedule III or IV drugs (P<0.001).

Future Directions Geographic analysis Data linkages with state mortality data Pediatric and Geriatric prescribing trends Prescribing trends among prescribers who are registered with PMP versus prescribers who are not registered

QUESTIONS?